The FlexISH assay brings flexibility to cytogenetic HER2 testing

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2559|69|4|635-646

ISSN： 0309-0167

Source： HISTOPATHOLOGY, Vol.69, Iss.4, 2016-10, pp. : 635-646

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Testing for HER2 Status

By  

Oncology, Vol. 61, Iss. 2, 2001-10 ,pp. : 22-30

Karger

Access to resources Recommend Favorite

Emerging Technologies for HER2 Testing

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 33-38

Karger

Access to resources Recommend Favorite

Current Status of HER2 Testing

By  

Oncology, Vol. 63, Iss. 1, 2002-11 ,pp. : 25-32

Karger

Access to resources Recommend Favorite

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2‐negative breast cancer

By  

CANCER, Vol. 120, Iss. 17, 2014-09 ,pp. : 2657-2664

John Wiley & Sons Inc

Access to resources Recommend Favorite

Development of a Molecular Cytogenetic Recombination Assay for Barley

By  

Cytogenetic and Genome Research, Vol. 129, Iss. 1-3, 2010-06 ,pp. : 154-161

Karger

Access to resources Recommend Favorite